已收盘 08-15 16:00:00 美东时间
-1.280
-0.99%
2025 Financial OutlookBased on its current operating plans, Karyopharm expects the following for full year 2025:Total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net
08-11 19:34
今日重点评级关注:花旗:维持Apellis Pharmaceuticals"买入"评级,目标价从46美元升至52美元;BTIG:维持Strategy"买入"评级,目标价从620美元升至700美元
08-04 09:30
J.P. Morgan analyst Brian Ossenbeck maintained a Buy rating on XPO today and se...
08-02 02:15
In a report released today, Christopher Kuhn from Benchmark Co. reiterated a Bu...
08-02 00:56
Wells Fargo analyst Christian Wetherbee maintains XPO (NYSE:XPO) with a Overweight and raises the price target from $144 to $147.
08-01 22:31
XPO, Inc. (NYSE: XPO) reported Q2 2025 financial results, with adjusted EPS of $1.05 beating analyst consensus. Revenue was $2.08B, slightly above estimates. North American LTL segment showed strong operational performance.
08-01 01:49
A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp.
08-01 01:21
XPO shares are trading lower. The company reported Q2 financial results.
08-01 00:11
XPO (NYSE:XPO) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $1.00 by 5 percent. This is a 6.25 percent decrease over earnings of $1.12 per share from the same period last
07-31 18:46
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32